Dernières nouvelles pour Biofrontera (NASDAQ:BFRI) Stock

Biofrontera

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Biofrontera Inc

Wells Fargo maintains Gen Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) with a Overweight and raises the price target from $35 to $37.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Gen Digital, Raises Price Target to $37

SM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.53 by 5.88 percent. This is a 6.36 percent decrease over earnings of $1.73 per share from the same period last year. The company reported quarterly sales of $643.61 million which missed the analyst consensus estimate of $651.37 million by 1.19 percent. This is a 0.42 percent increase over sales of $640.90 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

SM Energy Q3 Adj $1.62 Beats $1.53 Estimate, Sales $643.61M Miss $651.37M Estimate

CNO Finl Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNO#NYSE">CNO</a>) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.82 by 14.63 percent. The company reported quarterly sales of $1.130 billion which beat the analyst consensus estimate of $945.442 million by 19.52 percent. This is a 19.26 percent increase over sales of $947.500 million the same period last year.

CNO Finl Group Q3 2024 Adj. EPS $0.94 Beats $0.82 Estimate, Sales $1.130B Beat $945.442M Estimate

Willdan Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) raises FY2024 Adj EPS guidance from $2.00-2.10 to $2.15-2.25 vs $2.10 analyst estimate. Raises FY2024 sales outlook from $280.00 million-290.00 million to $285.00 million-295.00 million vs $290.05 million estimate.

Guidance

WLDN

Willdan Group Raises FY2024 Adj EPS Guidance from $2.00-2.10 to $2.15-2.25 vs $2.10 Est; Raises FY2024 Sales Guidance from $280.00M-290.00M to $285.00M-295.00M vs $290.05M Est

Camden Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $0.37 by 10.81 percent. The company reported quarterly sales of $387.20 million which missed the analyst consensus estimate of $389.39 million by 0.56 percent. This is a 0.92 percent decrease over sales of $390.78 million the same period last year.

Camden Prop Trust Q3 2024 Adj EPS $0.33 Misses $0.37 Estimate, Sales $387.20M Miss $389.39M Estimate

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) affirms FY2024 sales outlook from $56.00 million-64.00 million to $56.00 million-64.00 million.

CDXS

Codexis Affirms FY2024 Product revenues $38M-$42M, R&D revenues $18M-$22M.

United States Steel Corp Says Continue To Work Towards Closing Transaction With Nippon Steel By Year-End

Biotech

General

Bristol Myers Squibb Announced Topline Data From Its Phase 3 Study Of COBENFY That Showed Continuing Improvement In Symptoms Of Schizophrenia

Buybacks

Alamo Group Plans To Repurchase In Aggregate Up To $50M Of Its Outstanding Common Stock

Q4 2024 Outlook
We expect fourth quarter adjusted EBITDA in the range of $225 million and $275 million. Our North American Flat-Rolled segment results should decrease slightly, driven largely by lower lagging average selling price expectations for the quarter. We expect an improvement in Mini Mill segment results, even after accounting for $25 million of related start-up and one-time construction costs at BR2, reflecting an expected improvement in average selling prices. In Europe, results are expected to be lower given the absence of the positive CO2 allocations and weak underlying demand and pricing conditions. Our Tubular segment results should be largely consistent with the third quarter.

U.S. Steel Sees Q4 Adjusted EBITDA In The Range Of $225M-$275M

WIIM

AMCR

Amcor shares are trading lower after the company reported worse-than-expected Q1 financial results.

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) raises FY2024 FFO guidance from $1.36-1.39 to $1.39-1.40 vs $1.38 analyst estimate..

SBRA

Sabra Health Care REIT Raises FY2024 FFO Guidance from $1.36-1.39 to $1.39-1.40 vs $1.38 Est

United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.47 by 19.15 percent. This is a 60 percent decrease over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $3.85 billion which beat the analyst consensus estimate of $3.77 billion by 2.20 percent. This is a 13.04 percent decrease over sales of $4.43 billion the same period last year.

United States Steel Q3 Adj $0.56 Beats $0.47 Estimate, Sales $3.85B Beat $3.77B Estimate

VICI Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.67 by 4.48 percent. The company reported quarterly sales of $964.70 million which beat the analyst consensus estimate of $952.86 million by 1.24 percent. This is a 6.68 percent increase over sales of $904.32 million the same period last year.

VICI

VICI Props Q3 2024 GAAP EPS $0.70 Beats $0.67 Estimate, Sales $964.70M Beat $952.86M Estimate

VIAV

Viavi Solutions Sees Q2 Adj. EPS $0.09-$0.11 Vs $0.08 Est.; Revenue $255M-$265M Vs $248.60M Est.

Willdan Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.55 by 32.73 percent. This is a 97.3 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $75.69 million which beat the analyst consensus estimate of $72.60 million by 4.25 percent. This is a 15.94 percent increase over sales of $65.28 million the same period last year.

Willdan Group Q3 Adj $0.73 Beats $0.55 Estimate, Sales $75.69M Beat $72.60M Estimate

Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) reported quarterly losses of $(0.64) per share. This is a 28.89 percent increase over losses of $(0.90) per share from the same period last year. The company reported $4.28 million in sales this quarter. This is a 3.52 percent decrease over sales of $4.44 million the same period last year.

MRIN

Marin Software Q3 Adj $(0.64) Up From $(0.90) YoY, Sales $4.28M Down From $4.44M YoY

Wells Fargo analyst Edward Kelly maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $88 to $90.

Wells Fargo Maintains Overweight on Walmart, Raises Price Target to $90

License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS Markets Agreement expected to boost NeuroOne sales revenue and profitability
EDEN PRAIRIE, Minn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the execution of an amendment to its existing distribution agreement with Zimmer Biomet that will provide Zimmer Biomet with certain exclusive rights to distribute NeuroOne's OneRF&#x2122; Ablation System for use in the brain.

NMTC

NeuroOne Announces Expansion Of Existing Distribution Agreement With Zimmer Biomet For Commercialization Of OneRF Ablation System; NeuroOne Will Receive An Upfront Payment Of $3M; License Provides Exclusive Commercialization Rights For U.S. Distribution And Certain OUS Markets

Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) reported quarterly earnings of $6.13 per share which beat the analyst consensus estimate of $5.31 by 15.44 percent. The company reported quarterly sales of $5.651 billion which beat the analyst consensus estimate of $5.126 billion by 10.24 percent. This is a 9.66 percent increase over sales of $5.153 billion the same period last year.

Reinsurance Gr Q3 2024 Adj. EPS $6.13 Beats $5.31 Estimate, Sales $5.651B Beat $5.126B Estimate

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biofrontera (BFRI – Research Report), Gilead Science...

Analysts Offer Insights on Healthcare Companies: Biofrontera (BFRI), Gilead Sciences (GILD) and Ventyx Biosciences (VTYX)

The latest announcement is out from Biofrontera (BFRI). At the Company's Annual Meeting, stockholders cast their votes on several key issues. John ...

Biofrontera Stockholders Approve Key Governance Decisions

Biofrontera (BFRI) has provided an update. Biofrontera Inc. has announced the release of its new FDA-approved product, the RhodoLED&#xAE; XL, a cutting-...

Biofrontera Unveils RhodoLED® XL Lamp, Eyes Market Growth

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biofrontera (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfri-stock-quote/">BFRI</a>) just reported results for the second quarter of 2024.<ul><li>Biofrontera reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $7.89 million.</li><li>This was 3.86% worse than the analyst estimate for revenue of $8.21 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bfri-stock-earnings-biofrontera-for-q2-of-2024/">BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024

Biofrontera GAAP EPS of -$0.05 beats by $0.67, revenue of $7.84M beats by $0.38M

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

In a report released today, Bruce Jackson from Benchmark Co. maintained a Buy rating on Biofrontera (BFRI – Research Report), with a price target o...

Benchmark Co. Reaffirms Their Buy Rating on Biofrontera (BFRI)

Biofrontera ( ($BFRI) ) just unveiled an update. Biofrontera Inc. announced FDA approval for increasing the maximum dosage of its Ameluz&#xAE; gel from ...

Biofrontera's Ameluz Gel FDA Approval for Higher Dosage

Biofrontera announced top-line results in its Phase 3 study of the use of Ameluz with the BF-RhodoLED lamp in the treatment of sBCC. The double-bli...

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC

Biofrontera ( ($BFRI) ) has shared an announcement. Biofrontera Inc. announced promising results from its Phase 3 study on Ameluz&#xAE;-PDT for treating...

Biofrontera Announces Promising Phase 3 Study Results

BFFTF

BFRI

BFRIW

GILD

VTYX

Offerings

Press Releases

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Events

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Artelo Biosciences

Avenue Therapeutics

Aytu BioPharma

Cingulate

CNS Pharma

Enveric Biosciences

Evoke Pharma

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Hoth Therapeutics

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NRX Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Pulmatrix

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

TFF Pharmaceuticals

TNF Pharmaceuticals

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals

Benchmark

Roth Capital

Biofrontera shares are trading higher after the company announced top-line results in its Phase 3 study of the use of Ameluz with the BF-RhodoLED lamp in the treatment of sBCC.

Comments

Biofrontera

Actualités

Dernières nouvelles pour Biofrontera (NASDAQ:BFRI) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL